IBRX logo

ImmunityBio Stock Price

Symbol: NasdaqGS:IBRXMarket Cap: US$2.1bCategory: Pharmaceuticals & Biotech

IBRX Share Price Performance

US$2.41
-1.99 (-45.23%)
US$2.41
-1.99 (-45.23%)
Price US$2.41

IBRX Community Narratives

There are no narratives available yet.

IBRX Community Fair Values

    Recent IBRX News & Updates

    No updates

    ImmunityBio, Inc. Key Details

    US$31.2m

    Revenue

    US$58.0k

    Cost of Revenue

    US$31.2m

    Gross Profit

    US$440.3m

    Other Expenses

    -US$409.1m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -0.46
    Gross Margin
    99.81%
    Net Profit Margin
    -1,310.30%
    Debt/Equity Ratio
    -132.4%

    ImmunityBio, Inc. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About IBRX

    Founded
    n/a
    Employees
    671
    CEO
    Richard Adcock
    WebsiteView website
    immunitybio.com

    ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

    U.S. Market Performance

    • 7 Days: -1.2%
    • 3 Months: 13.1%
    • 1 Year: 22.8%
    • Year to Date: 7.3%
    Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading